Sotatercept PAH Right Heart Gains – Anjali Vaidya, MD
Sotatercept & Pulmonary Arterial Hypertension: Key Findings from the Interview
Hear’s a breakdown of the key takeaways from the interview with Dr. Vaidya regarding sotatercept’s impact on Pulmonary Arterial Hypertension (PAH):
Overall Effects:
* Sotatercept significantly improves right ventricular size, right ventricular function, and tricuspid regurgitation in PAH patients.
* Improvements are seen in key hemodynamic and structural parameters.
Specific Changes at Week 24:
* sPAP (Systolic Pulmonary Artery Pressure): Improved significantly.
* Pulmonary vascular Resistance: Improved significantly.
* Right Ventricle Size: Important improvements in end-diastolic area and end-systolic area and volumes.
* TAPSE (Tricuspid Annular Plane Systolic Excursion): Did not show statistically significant improvement at week 24, likely as it was normal at baseline, limiting further augmentation.
* TAPSE/sPAP Ratio: Did improve significantly, reflecting the benefit of reduced sPAP.
* Right Ventricular Fractional Area Change: Showed significant improvement, capturing both longitudinal and transverse contraction.
Longer-Term Data (PULSAR Study – 18-24 months):
* TAPSE: Did show improvement with longer-term sotatercept use.
Tricuspid Regurgitation:
* Dramatic Improvement: 92% of patients on sotatercept had insignificant tricuspid regurgitation (none, trace, or mild) at 24 weeks, compared to 78% on placebo.
Prognostic Importance of Improved TR & TAPSE:
* Combined Benefit: Mild or less tricuspid regurgitation combined with TAPSE ≥1.8 cm or 1.9 cm is strongly linked to improved transplant-free survival in PAH patients.
* TR as a Prognostic Marker: The severity of tricuspid regurgitation correlates with overall survival and prognosis in PAH,reflecting right heart dysfunction.
* TAPSE & TR Interaction: Patients with normal TAPSE and insignificant tricuspid regurgitation have significantly better survival outcomes than those with normal TAPSE but significant tricuspid regurgitation.
In essence, sotatercept appears to address key aspects of PAH pathology, leading to improvements in right heart function and structure, and ultimately potentially improving long-term outcomes for patients.